Two Sigma Advisers’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-370,500
| Closed | -$2.16M | – | 2825 |
|
|
2022
Q4 | $2.16M | Sell |
370,500
-117,800
| -24% | -$619K | 0.01% | 1198 |
|
|
2022
Q3 | $3.27M | Buy |
488,300
+340,700
| +231% | +$2.07M | 0.01% | 941 |
|
|
2022
Q2 | $621K | Buy |
147,600
+82,000
| +125% | +$324K | ﹤0.01% | 1828 |
|
|
2022
Q1 | $221K | Sell |
65,600
-29,800
| -31% | -$94.5K | ﹤0.01% | 2352 |
|
|
2021
Q4 | $301K | Buy |
95,400
+45,900
| +93% | +$153K | ﹤0.01% | 2142 |
|
|
2021
Q3 | $162K | Buy |
49,500
+3,200
| +7% | +$11.2K | ﹤0.01% | 2283 |
|
|
2021
Q2 | $195K | Sell |
46,300
-33,700
| -42% | -$143K | ﹤0.01% | 2276 |
|
|
2021
Q1 | $399K | Sell |
80,000
-13,200
| -14% | -$107K | ﹤0.01% | 2104 |
|
|
2020
Q4 | $1.18M | Sell |
93,200
-8,000
| -8% | -$91.2K | ﹤0.01% | 1486 |
|
|
2020
Q3 | $994K | Sell |
101,200
-22,192
| -18% | -$219K | ﹤0.01% | 1500 |
|
|
2020
Q2 | $1.23M | Buy |
123,392
+492
| +0.4% | +$4.72K | ﹤0.01% | 1475 |
|
|
2020
Q1 | $1.09M | Buy |
122,900
+8,100
| +7% | +$79.9K | ﹤0.01% | 1437 |
|
|
2019
Q4 | $1.06M | Buy |
114,800
+6,000
| +6% | +$42.5K | ﹤0.01% | 1551 |
|
|
2019
Q3 | $640K | Buy |
108,800
+4,400
| +4% | +$46.7K | ﹤0.01% | 1616 |
|
|
2019
Q2 | $1.25M | Buy |
104,400
+44,800
| +75% | +$482K | ﹤0.01% | 1416 |
|
|
2019
Q1 | $719K | Sell |
59,600
-8,800
| -13% | -$130K | ﹤0.01% | 1649 |
|
|
2018
Q4 | $858K | Sell |
68,400
-4,700
| -6% | -$64.9K | ﹤0.01% | 1556 |
|
|
2018
Q3 | $1.08M | Buy |
73,100
+4,200
| +6% | +$66.1K | ﹤0.01% | 1476 |
|
|
2018
Q2 | $1.16M | Buy |
68,900
+25,000
| +57% | +$486K | ﹤0.01% | 1551 |
|
|
2018
Q1 | $1M | Sell |
43,900
-13,938
| -24% | -$310K | ﹤0.01% | 1542 |
|
|
2017
Q4 | $1.5M | Buy |
+57,838
| New | +$1.16M | ﹤0.01% | 1379 |
|
|
2016
Q4 | – | Sell |
-11,600
| Closed | -$117K | – | 2485 |
|
|
2016
Q3 | $117K | Sell |
11,600
-6,100
| -34% | -$66.6K | ﹤0.01% | 2119 |
|
|
2016
Q2 | $199K | Buy |
17,700
+1,300
| +8% | +$16.6K | ﹤0.01% | 1862 |
|
|
2016
Q1 | $224K | Buy |
+16,400
| New | +$236K | ﹤0.01% | 1791 |
|
|
2015
Q2 | – | Sell |
-27,400
| Closed | -$415K | – | 2124 |
|
|
2015
Q1 | $415K | Buy |
+27,400
| New | +$382K | ﹤0.01% | 1438 |
|
Two Sigma Advisers's CNCE Position: Q1 2023 in Review
Two Sigma Advisers sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 370,500 shares — an estimated $2.16M sold.
Two Sigma Advisers first reported a position in CNCE in Q1 2015 and held it in 25 quarters. The position peaked at $3.27M in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Two Sigma Advisers reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Two Sigma Advisers sold 370,500 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.16M.
- Two Sigma Advisers first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 25 quarters.
- Two Sigma Advisers's Concert Pharmaceuticals, Inc. position peaked at $3.27M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Two Sigma Advisers's 13F filing for Q1 2023, filed 15 May 2023.